




































      
    
    

















































































































































          
 
   
      





























































































































               
 










































































Chitosan, a  biopolymer comprising glucosamine and N-
cetylglucosamine residues, is an N-deacetylated product of chitin,
s well as one of the most abundant polysaccharides in  nature [1].
his cationic polysaccharide has been widely used in a variety of
harmacological and biomedical applications, besides as a dietary
upplement, owing to its claimed biological properties (e.g. antiox-
dant, prebiotic, antimicrobial and cholesterol regulator), which
ight be used to human benefit [2].  However, its high molecu-
ar weight (MW),  which hampers solubility in acid-free aqueous
edia, has limited its practical applications [3]. Recent studies per-
aining to chitosan have focused on conversion thereof to water
oluble oligosaccharides.
Chitooligosaccharides (COS) – depolymerized products of chi-
osan obtained by chemical or enzymatic hydrolysis, have recently
ttracted much attention as potential nutraceutical agents. These
hitosan derivatives (generally, the MW of COS is 10 kDa or less)
4], also seem to possess several biological properties as prebiotic,
ntioxidant, antibacterial and anti-inflammatory among others
5–7]. Furthermore, their ready uptake by cells, namely intestine
ells, makes theoretically possible for COS to be accessible to the
∗ Corresponding author at: Escola Superior de Biotecnologia, Rua Dr. António
ernardino de Almeida, P-4200-072 Porto, Portugal. Tel.: +351 967892999;
ax: +351 22 5090351.
E-mail address: jfernandes@email.com (J.C. Fernandes).
     entire human body, enhancing the range of possible applications
for COS [3].
Despite the extensive studies on the biological activities of chi-
tosan and COS, there is no strong experimental evidence available
regarding the biocompatibility of COS. In vitro and in vivo evalua-
tions of chitosan toxicity have been reported elsewhere [1,8,9], and
considered it as a biocompatible polymer. Yet, some studies also
reported cell toxicity dose-dependent [10–12].  With regard to COS,
the studies are even scarcer, mainly based on the MTT  colorimet-
ric assay, and reported contradictory conclusions: Rajapakse et al.
reported the absence of toxic effects by COS, at 0.050–1.0 mg/mL
upon human and mouse leukocyte cell lines [13], but Xu et al.
claimed that at 0.80 mg/mL  COS induces apoptosis upon human
cells [14].
In view of the above, the main objective of this study was to
evaluate the biocompatibility of COS by studying their cytotox-
icity and/or their mutagenic potential, upon human lymphocyte
cultures.
2. Materials and methods
2.1. MaterialsTwo  COS mixtures, named COS3 and COS5, were purchased
from Nicechem (Shanghai, China). Low MW  chitosan (LMWC) was
purchased from Sigma–Aldrich (Sintra, Portugal). All said com-




























































       
xperimental work were purchased from Sigma–Aldrich (Sintra,
ortugal).
.2. Characterization of chitooligosaccharides
The average MW  of both COS mixtures was assessed by size
xclusion chromatography (SEC). Two combined TSKGel series
olumns (G2500PWXL × G5000PWXL) together with a PWXL guard
olumn were used, coupled with a RID-10A Shimadzu refractive
ndex (RI) detector. A  flow rate of 0.8 mL  min−1 and a mobile
hase solution of 0.5 M AcOH–0.2 M AcONa at pH 4.4–4.5 (25 ◦C),
ere found to be the most suitable conditions to evaluate COS
olecular weight. Pullulan (TOSOH Biosciences) of different molec-
lar weights were used as standards to calibrate the column,
nd quantification of COS was performed by external calibration,
sing chitobiose as standard. Data provided by the SEC-HPLC sys-
em were collected and analyzed using the Chromeleon system
ersion 6.7. The DD was determined using a FT-IR Perkin Elmer
nfrared spectrometer. An aliquot of COS sample was  mixed with
otassium bromide (1:1000) and compressed into pellets. The IR
pectra were recorded and the absorbance values of the suitable
bsorption bands were calculated using the base line method. The
D was calculated from the value of the absorption band ratio
amide peak/Areference peak.  A number of absorption band ratios have
een proposed in the literature, differing either in the band selected
s in the internal reference band. One such band ratio is A1655/A3450,
etermined using a line draw from 4000 cm−1 to 2500 cm−1 as
he base line for the hydroxyl group band, and one drawn from
800 cm−1 to 1600 cm−1 as the base line for the Amide I band [16].
he DD was thus calculated according to  the following equation:






his procedure has been found to give results in agreement with
hose given by dye absorption [15,16] for samples having a degree
f N-acetylation within the range 0–55%.
.3. Evaluation of genotoxicity by cytokinesis-blocked
icronucleus assay
Fresh peripheral blood samples were collected from healthy
olunteers, into heparinized vacutainers. The blood samples were
uspended in RPMI 1640 culture medium, supplemented with 10%
w/v) fetal bovine serum (FBS), l-glutamine, and penicillin; phyto-
aemagglutinin, at 1% (w/v), was used as a mitogen to stimulate
ymphocyte mitosis. In all sets of experiments (n = 3), a negative
ontrol (whole blood in PBS) was used, as well as a positive con-
rol (using the mutagenic agent, cyclophosphamide, at 5 mg/mL).
ither COS mixture and LMWC  were tested at  4 different concentra-
ions – 1.0, 0.1, 0.01 and 0.001 mg/mL. Duplicate cultures were set
p for each experimental point, within 60 min  after venipuncture.
ytochalasin B, an inhibitor of the mitotic spindle that prevents
ytokinesis, was added (5 mg/mL) at 44 h of incubation; blood cell
ultures were incubated at  37 ◦C  for 72 h after experiment initia-
ion. The lymphocytes were then isolated from the other blood cells
y density gradient separation (Histopaque-1077 and -1119) and
dditional 2 washing steps were performed with 3% (v/v) FBS saline
olution with. The lymphocytes were fixed in 3:1 methanol/glacial
cetic acid, dropped onto clean microscopic slides, air-dried and
tained with Wright stain. For each sample, 1000 binucleated lym-
hocytes were blindly scored using a Leica light optical microscope
Wetzlar, Germany), following the scoring criteria outlined else-
here [17];  the numbers of micronuclei, nucleoplasmic bridges and
uclear buds per 1000 binucleated lymphocytes, were recorded.
he nucleous division index (NDI), a measure of the cell division
inetics, was scored in the same slides, according to the method   
of Eastmond and Tucker [18]; accordingly, 500 viable cells were
counted to determine the frequency of lymphocytes with 1, 2,  3 or
4 nuclei, and the NDI calculated using the formula:
NDI = M1  + 2M2  +  3M3  + 4M4
N
,
where M1–M4 represent the number of lymphocytes with 1–4
nuclei, respectively, and N is the total number of viable cells scored
(excluding necrotic and apoptotic cells).
2.4. Evaluation of genotoxicity by the comet alkaline assay
Fresh peripheral blood samples were collected and treated, as
described above for cytokinesis-blocked micronucleus assay. Fol-
lowing the guidelines proposed by Tice et al. [19],  10 L of treated
or control lymphocytes (ca. 104 cells) was  added to 120 L of
0.5% (w/v) low-melting point agarose at 37 ◦C, layered onto a pre-
coated slide with 1.5% (w/v) regular agarose and, finally, covered
with a coverslip. After brief agarose solidification under refriger-
ated conditions, the coverslip was  removed, and the slides were
immersed in a lysing solution – consisting of 2.5 M sodium chloride,
100 mM ethylenediaminetetraacetic acid (EDTA), 10 mM Tris–HCl
buffer at pH 10 (Sigma–Aldrich), 1% (w/v) sodium sarcosinate
(Sigma–Aldrich) with 1% (w/v) Triton X-100 (Sigma–Aldrich) and
10% (w/v) dymethylsulfoxide (DMSO). Just prior to electrophore-
sis, the slides were left for 20 min  in an alkaline buffer containing
0.3 mM NaOH (Merck) and 1 mM  EDTA (pH > 13); electrophoresis
was then carried out for 20 min, at 25 V (0.86 V/cm) and 300 mA.
Afterwards, the slides were neutralized in 0.4 M Tris–HCl (pH =  7.5),
fixed in absolute ethanol and stored at room temperature, until
analysis. In order to minimize extraneous DNA damage caused
by ambient ultraviolet radiation, all steps were performed with
reduced illumination.
2.5. Evaluation of cytotoxicity by flow cytometry
Fresh peripheral blood samples were collected from healthy
volunteers, into heparinized vacutainers. Lymphocytes were then
isolated by density gradient separation (Histopaque-1077 and -
1119). Three extra washes with a cold saline solution containing
3% (w/v) FBS were performed. The viability of the lymphocytes
was evaluated by the trypan blue exclusion test, using a Neubauer
counting chamber. Lymphocytes were then resuspended, at a con-
centration of 1 × 106 viable cells/mL, in RPMI 1640 culture medium,
supplemented with 10% (w/v) FBS, l-glutamine and penicillin. In all
sets of experiments (n = 3), a negative control (with PBS) was used,
as well as a positive control with staurosporine at 4  M –  a strong
cytotoxic alkaloid added 8 h before the end of incubation. Either
COS mixtures and LMWC  were added to the lymphocyte suspen-
sions at the 4 concentrations used in the other assays – 1.0, 0.1,
0.01 and 0.001 mg/mL, and incubated for 24 h at 37 ◦C. The assay
was performed in a  96-well plate, and each tested condition had
4 replicates. After incubation, the cells were washed twice with
a cold saline solution, and then stained according to the general
Annexin V staining procedure by BD Biosciences (Annexin V-PE
Apoptosis detection kit I, BD Biosciences, San Diego, US): the cells
were resuspended in 1× binding buffer, to obtain a cell density of
ca. 105 cells; Annexin V and 7-Aminoactinomycin D (7AAD) were
then added, and the samples incubated for 15 min  at room temper-
ature, in the dark; 400 l  of 1× binding buffer was  finally added
to each tube. The treated samples and controls were analyzed by
flow cytometry within a  1 h  period [20,21].  Flow cytometric anal-
ysis was  carried out in a FACS Calibur (San Jose, CA, USA) based
on the acquisition of 20,000 events. Detectors for forward (FSC)
and side (SSC) light scatter were set on a linear scale, whereas log-
arithmic detectors were used for all three fluorescence channels
           
Table  1
Major characteristics (average or average ± standard deviation) of COS3, COS5 and
LMWC,  determined by SEC and FTIR.
Compound MW (kDa) DD (%)

















































Results of the cytokinesis-blocked micronucleus assay (average or aver-
age ± standard deviation), for COS3, COS5 and LMWC,  at several concentrations.
MW Concentration (mg/mL) MN/1000 binucleated cells NDI
C (−) – 3.00 ±  0.71 1.53
C  (+) 5.0 14.50 ±  2.12* 1.38
COS3
1.0  3.00 ±  1.41 1.30
0.1  2.50 ±  0.71 1.42
0.01  1.50 ±  0.71 1.51
0.001 2.50 ±  0.71 1.50
COS5
1.0  2.50 ±  0.71 1.29
0.1  2.50 ±  0.71 1.40
0.01  2.00 ±  0.00 1.49
0.001 3.50 ±  0.71 1.52
LMWC
1.0  2.50 ±  2.12 1.43
0.1  3.50 ±  0.71 1.47
0.01  1.50 ±  2.12 1.48
0.001 2.50 ±  0.71 1.48
Lymphocytes treated with high concentrations of COS, showed
a significant increase in non-viable cells when compared with the
negative control (Fig. 1); at 1.0 mg/mL  the percentage of non-viable
Table 3
Results of the comet alkaline assay (average or average ±  standard deviation), for
COS3, COS5 and LMWC, at several concentrations.
MW  Concentration (mg/mL) Tail length (m) Tail moment (%)
C (−) – 41.02 ± 5.32 0.612
C  (+) 5.0 103.3 ± 18.1* 9.58*
COS3
1.0 43.19 ± 7.41 0.696
0.1  42.86 ± 4.08 0.640
0.01  40.15 ± 6.35 0.612
0.001 40.32 ± 2.28 0.612
COS5
1.0  44.08 ± 7.07 0.702
0.1  42.57 ± 7.14 0.648
0.01  40.35 ± 5.14 0.611
0.001 39.86 ± 2.12 0.608
1.0  41.63 ± 5.12 0.623COS5 4.134 ± 0.6 66.24 ± 0.48
LMWC  125.6 ± 4.2 70.23 ± 0.93
FL-1, FL-2 and FL-3). Compensation for spectral overlap between
L channels was performed for each experiment using single-color-
tained cell populations of positive control. All data were collected
ngated to disk and were analyzed using CELLQuest Pro software.
ymphocytes were then analyzed for their expression of Annexin
nd 7AAD to determine the number of viable cells: Annexin V  and
AAD negative (Annexin V−/7AAD−); cells undergoing apoptosis,
nnexin V  positive and 7AAD negative (Annexin V+/7AAD−); and
ead cells or cells that were in latest stage of apoptosis, Annexin
nd 7-AAD positive (Annexin V+/7AAD+).
.6. Confocal analysis
FITC-labeled COS was synthesized by adding 100 ml  of dehy-
rated methanol followed by 50 ml  of FITC in methanol (2.0 mg/ml)
o 100 ml  of COS (10.0 mg/mL  of water) in the dark at ambient tem-
erature. After 3 h, the labeled polymer was precipitated in 0.2 M
aOH. After centrifugation of the precipitated product at 6000 rpm
or 10 min, the supernatant solution was discarded to recover the
roduct. Five ml  of Milli-Q water with a few drops of 1  N HCl was
hen added and the product was dissolved again. This purifica-
ion process was repeated five times until fluorescence from FITC
ould not be detected in the supernatant. The FITC-labeled COS
as then freeze-dried. Following a procedure similar to the evalua-
ion of cytotoxicity, FITC labeled COS was added to the lymphocyte
uspensions at 0.1 mg/mL, and incubated for 8  h at 37 ◦C, in the
ark. After incubation, the cells were washed twice with a cold
aline solution, and then were resuspended to obtain a cell density
f ca. 105 cells. The lymphocytes were than dropped onto glass,
tained with DAPi (250 L of a  300 nM solution, for 10 min) and
ith Alexa Fluor 568 (500 L of a  1 g/mL solution, for 10 min),
nd finally mounted in Vectashield (Vector Laboratories, Peterbor-
ugh, UK). The samples were examined under an inverted confocal
icroscope (CLSM, Zeiss Axiovert 200M, Oberkochen, Germany)
quipped with a LSM 5 Image Browser (Carl Zeiss, Oberkochen,
ermany).
.7. Statistical analyses
Mean values and standard deviations were calculated from the
xperimental data obtained, and analysis of variance (ANOVA) was
pplied to a 5% level of significance, using compound concentration
nd MW as main factors. Pairwise comparisons were done using
he Bonferroni test, at the same level of significance. All statistical
nalyses were performed using the SPSS package program version
6.0.
. Results
The major characteristics of the COS mixtures and LMWC  are
isted in Table 1.
The potential genotoxic effect of COS3, COS5 and LMWC  on lym-
hocytes was determined by the cytokinesis-blocked micronucleus
ssay (Table 2). No significant differences on micronucleus-
orming activity as a function of  concentration or MW were
bserved (P  > 0.05). Micronuclei were scored in populations of 1000
inucleated lymphocytes, either as  micronucleated binucleatedNDI: nucleous division index; MN:  micronucleus.
* P  < 0.05.
cells, or as total number of micronuclei. The use of cyclophos-
phamide (positive control) induced almost a  5-fold increase in the
micronucleus-forming activity, as compared to the negative con-
trol.
Values for the NDI are also depicted in Table 2. This cell divi-
sion kinetics index presented significant differences dependent on
concentration and MW:  COS3 and COS5, when at 1.0 mg/mL, lead
to significant lower NDI values than those observed for the other
COS concentrations, and also observed for the negative control and
for all the LMWC  concentrations tested; however, such NDI val-
ues produced by 1.0 mg/mL  COS3 and COS5, were similar to those
presented by the positive control.
The results for the comet assay are shown in Table 3. The comet
tail length (CTL) and tail moment (CTM) were estimated for each
concentration, based on populations of 100 lymphocytes, since it is
widely accepted that CTL and CTM are directly proportional to the
extent of DNA damage [22,23].  Analysis of variance of CTL and CTM
did not reveal significant differences (P > 0.05) between negative
control and lymphocytes treated with COS/LMWC. However, both
CTL and CTM of  lymphocytes treated with cyclophosphamide (pos-
itive control) were significantly higher than those of the negative
control, and those with COS/LMWC.LMWC
0.1  40.25 ± 3.35 0.607
0.01  40.79 ± 2.87 0.612
0.001 40.74 ± 3.92 0.611
* P  < 0.05.
        
























1.0 mg/mL, possess a  cytostatic effect; since the NDI values (≤1.30)
F
d
owing treatment with COS3, COS5 or LMWC  for 24 h, at 37 ◦C (average ± standard
eviation).
ells were above 90.0%, and were even higher than those exhib-
ted by the positive control, ca. 70% (treated with staurosporine);
ymphocytes treated with 1.0 mg/mL  of LMWC,  showed a signifi-
ant lower fraction of dead cells (ca. 30%) compared to  COS3 and
OS5, and to the positive control; lower concentrations (0.01 and
.001 mg/mL) of COS and LMWC  led to results similar to those pre-
ented by the negative control (i.e. <10%).
Further analyses with flow cytometry were performed, in order
o follow the percentage of apoptotic and necrotic cells present
n the lymphocyte populations treated with COS3 and COS5, at
oncentrations similar or higher than 0.01 mg/mL  – above which
e observed changes in the viability of the lymphocytes (Fig. 2).
he extent of apoptosis in cells treated with staurosporine was
bout 60.1%; this apoptosis value was significantly higher than
hat induced by COS at any concentration tested (P < 0.05). Above
.50 mg/mL, both COS induced necrosis higher than 70%, and apo-
tosis below 10% (data not shown). As COS concentration was
ecreased, the necrosis rate also decreased; in contrast, apoptosis
tarted to increase until a  maxima of 22.1% (for COS3 at 0.20 mg/mL)
r of 34.7% (for COS5 at 0.30 mg/mL); at these concentrations, the
ecrosis values are statistically higher than the negative and posi-
ive controls (P < 0.05). Although the percentage of non-viable cells
ig. 2. Necrotic (Annexin V+/7AAD+) and apoptotic (Annexin V+/7AAD−) lymphocytes, fo
eviation).   
were approximately the same for either COS at the same concen-
tration (P > 0.05), the level of apoptosis was always higher in the
case of COS5. Conversely, the necrosis percentages were higher
for COS3 (except at 0.50 mg/mL); below 0.070 mg/mL, the values
became statistically identical between negative control and both
COS mixtures.
4. Discussion
In this research effort, we aimed to explore the relation between
the MW and concentration, and toxicological effects, of two COS
mixtures and a LMWC.  Although chitosan has been the subject of
intense studies and claimed to  be a non-toxic biocompatible poly-
mer in several reports [24–26],  COS safety has not to date been
comprehensively assessed in cytogenetic terms.
Biocompatibility of a compound refers to the extent to which
its molecule does not have toxic effects or cause injury upon bio-
logical systems. To consider it as biocompatible, it is thus of great
importance to submit the molecule under study to a  number of
pre-toxicity tests, in vitro or in vivo [25]. In vitro tests are faster and
ethically less demanding, so they were selected here; in addition,
they are usually more reproducible and sensitive, besides allowing
cellular and molecular reactions to be handled outside the organ-
ism, in a simple manner.
The cytokinesis-blocked micronucleus assay is a genotoxicity
test that provides simultaneous information on a variety of chro-
mosomal damage endpoints that may  reflect chromosomal loss,
breakage and rearrangement, as well as gene amplification [27].
This assay has been routinely used in mutagen/carcinogen screen-
ing programs, to detect agents that cause chromosomal damage
and spindle dysfunction [28]. Our results showed that COS and
LMWC  do not possess mutagenic potential at the studied con-
centrations, as they did not present differences in micronuclei
frequency, as compared with the negative control (P >  0.05); indeed,
as the micronucleus frequency induced by different concentrations
and MW was  essentially constant, we may  say that the absence
of genotoxic effects upon human lymphocytes of COS and LMWC
appears to be MW-  and dose-independent.
The NDI is useful to compare the mitogenic response of lym-
phocytes and the cytostatic effects of the agents under study, as
it provides a measure of the proliferative status of the viable cell
fraction, thus being also a useful biomarker of immune function
[29]. The NDI values showed clearly that both COS mixtures, atwere considerably lower than the negative control, meaning that
a major fraction (70%) of the viable lymphocytes failed to undergo
cell division.
llowing treatment with the two COS mixtures for 24 h, at 37 ◦C (average ±  standard






























































Fig. 3. Microphotograph of lymphocytes after 8 h incubation with FITC-labeled COS
using a stain for DNA (blue – dapi) and a  stain for cell membrane (red – Alexa Fluor       
The comet assay constitutes an alternative approach to geno-
oxic studies, and we used it  to confirm the absence of genotoxic
ffects by COS. In this test, cells exhibiting an increased frequency
f DNA double strand breaks, display an increased rate of migration
f DNA. In addition, due to the prevailing alkaline conditions, this
est also offers enhanced sensitivity to identify genotoxic activity,
hich tends to induce more single strand breaks and alkali-labile
ites than double strand breaks [19,30]. This assay has, indeed,
een widely claimed to be more sensitive than CBMN (and Ames)
est. Measurements of the tail length of released damaged DNA are
escribed to correlate well with the mutagenic and carcinogenic
roperties of the compounds under study [25,31].
Our comet assay results confirmed the parallel CBMN assay
esults: COS and LMWC  did not exhibit genotoxic effects upon
uman lymphocytes. Recall that the tail length – i.e. the distance of
NA migration from the body of the nuclear core, is used to evalu-
te the extent of DNA damage; on the other hand, the tail moment
onstitutes a measure of both the smallest detectable size of migrat-
ng DNA (reflected in the comet tail length) and of the number of
elaxed/broken pieces (represented by the intensity of DNA in the
ail). Both tail length and moment were not significantly affected
y COS and LMWC  compared with negative control. In contrast,
he DNA damage in cells exposed to cyclophosphamide was signif-
cantly higher – the damaged DNA actually migrated almost 3-fold
ore than all the other tested samples. This absence of DNA damage
s most likely related to the reported protective effects of COS upon
amaged DNA [32]; however, such protective actions have not yet
een fully elucidated. In vivo studies by Yoon et al., showed that COS
id not affect the frequency of micronucleus or chromosomal aber-
ations in bone marrow cells, independently of the concentrations
f COS [33].
A number of studies have meanwhile shown that chitosan
nduces apoptosis in vitro [34–36] and in vivo [37]; however, data
egarding COS are essentially few and inconclusive. Flow cytom-
try can provide rapid, quantitative and objective evaluation of
ell viability, and may  further provide enumeration of apoptotic or
ecrotic cells. It has become the method of choice to assay for apo-
tosis and necrosis in a variety of cell systems. The double-staining
nnexin V/7-AAD assay discriminates cells that are undergoing
arly or late apoptosis and necrosis [38].  Hence, we chose this
ethod to provide a broader understanding of the cytotoxic effects
f COS upon lymphocytes.
Our experimental data demonstrated that COS at high con-
entrations (1.0–0.1 mg/mL), independently of their MW,  exerted
trong cytotoxic effects against human lymphocytes – which were
learly dose-dependent. LMWC  showed a significantly lower toxic-
ty than either COS mixtures (P < 0.01) at high concentrations, thus
uggesting that COS are much more toxic than chitosan. Due to the
ationic nature of chitosans and COS, the surface charge of these
olecules has been claimed as the major factor affecting said cyto-
oxic activity, owing to  the electrostatic interaction between the
egatively charged groups of the lymphocyte surface (i.e. glyco-
roteins) and the positively charged amino groups of chitosans and
OS [39]. Since the DD is approximately the same for LMWC  and
oth COS mixtures (Table 1), we may  hypothesize that chain length
lays a crucial role upon induction of cytotoxicity.
COS have previously been reported to be more reactive than
MWC  [40].  Furthermore, as we have previously reported [41],  high
oncentrations (i.e. 1.0–0.5 mg/mL) of COS induced oxidative stress
n cells via a pro-oxidant effect, opposed to the effect produced by
MWC  at the same concentration; and damaged cell membranes
s well, via binding to  its proteins [40]. The induction of oxidative
tress when at high concentrations may  be a  possible mechanism
f induction of toxicity by COS, as oxidative conditions have been
idely reported as responsible for inducting cytotoxic effects upon
uman cells: Yang et al. showed that oxidative stress was the key568).  (For interpretation of the references to color in this figure legend, the reader
is referred to the web version of the article.)
route cytotoxicity induction by several nanoparticles on fibroblasts
cells [42]; Arakaki et al. reported the involvement of oxidative stress
in tumor cytotoxic activity [43]; and Patlolla et al. described cyto-
toxicity, induced by potassium dichromate, upon HepG2 cells to be
mediated by oxidative stress [44].
Another feature of COS that we have described [40], was  their
ability to induce changes in cell membranes. Confocal microscopy
permitted us to conclude that COS did not just link to the lympho-
cyte membrane, but they were also able to penetrate the membrane
and, eventually, bind to nucleolus (Fig. 3). On the contrary, LMWC
could not enter directly into the cell, but merely interact with the
cell membrane (data not shown).
Takimoto et al. have demonstrated that chitosan induces apo-
ptosis via caspase-3 activation [36]. Our data indicated that LMWC
induced cellular death (ca. 30% at 1.0 mg/mL) mainly by apoptosis as
well. However, COS (when at high concentrations) seem to induce
cell death, mainly, via necrosis (quick process, in which cells lose
their membrane integrity and, thus, die rapidly as a result of cell
lysis); when COS concentrations decrease (<0.10 mg/mL), the pri-
mary mechanism of cell death switches to apoptosis. It has been
documented that the mode of cell death may  depend on the cell
type, the type/concentration of stimulus, and environmental set-
ting [45]; our results suggest that the mode of cell death varies with
the concentration and the type (i.e. MW)  of the chitosan derivative
tested.
In summary, our experimental results suggest that chitosan
oligomers do not exhibit any genotoxicity upon human lym-
phocytes, independently of MW or concentration. However, COS
cannot be considered biocompatible molecules at levels above
0.07 mg/mL, since they appear to induce a strong cytotoxic
effect upon the lymphocytes – concentration and chain length-
dependent. According to the concentration used, such cytotoxicity
will induce cell death, essentially via necrosis (>0.10 mg/mL)
or apoptosis (<0.10 mg/mL). Below 0.07 mg/mL, neither COS nor
LMWC  produced toxic effects, suggesting that these molecules will
be harmless to human cells under those conditions.
In any case, further studies are recommended, mainly in vivo
tests, to eventually confirm these in vitro results, especially aiming
at assuring COS and LMWC  safe concentrations.
AcknowledgementsFunding for author J.C. Fernandes was  via a PhD fellowship (ref.





































       
eferences
[1] X. Zhang, D. Yang, J. Nie, Int. J. Biol. Macromol. 43 (2008) 456–462.
[2] Y. Park, M.H. Kim, S.C. Park, H. Cheong, M.K. Jang, J.W. Nah, K.S. Hahm, J. Micro-
biol. Biotechnol. 18 (2008) 1729–1734.
[3] S.Y. Chae, M.K. Jang, J. Nah, J. Control. Release 102 (2005) 383–394.
[4] K.M. Vårum, M.H. Ottøy, O. Smidsrød, Carbohydr. Polym. 25 (1994) 65–70.
[5] P.  Eaton, J.C. Fernandes, E. Pereira, M.E. Pintado, F.X. Malcata, Ultramicroscopy
108 (2008) 1128–1134.
[6] S.-K. Kim, N. Rajapakse, Carbohydr. Polym. 62 (2005) 357–368.
[7] V.I. Gorbach, I.N. Krasikova, P.A. Luk’yanov, Y.N. Loenko, T.F. Solovéva, Y.S.
Ovodov, V.V. Deev, A.A. Pimenov, Carbohydr. Res. 260 (1994) 73–82.
[8] J.H. Kim, J.-H. Bae, K.T. Lim, P.-H. Choung, J.-S. Park, S.J. Choi, A.L. Im,  E.T. Lee,
Y.-H. Choung, J.H. Chung, J.  Biomed. Mater. Res. A 90 (2009) 446–455.
[9] W.F. Zhang, H.Y. Zhou, X.G. Chen, S.H. Tang, J.J. Zhang, J.  Mater. Sci. Mater. Med.
20  (2009) 1321–1330.
10] B. Carreno-Gomez, R. Duncan, Int. J. Pharm. 148 (1997) 231–240.
11] T. Mori, M. Okumura, M.  Matsuura, K. Ueno, S. Tokura, Y. Okamoto, S. Minami,
T.  Fujinaga, Biomaterials 18 (1997) 947–951.
12] N.G.M. Schipper, S. Olsson, J.A. Hoogstraate, A.G. deBoer, K.M. Vårum, P. Arturs-
son, Pharm. Res. 14 (1994) 923–929.
13] N. Rajapakse, M.-M.  Kim, E. Mendis, S.-K. Kim, Bioorg. Med. Chem. 15 (2007)
997–1003.
14] Q. Xu, J. Dou, P. Wei, C. Tan, X.  Yun, Y. Wu,  X. Bai, X. Ma,  Y. Du, Carbohydr. Polym.
71  (2008) 509–514.
15] S.C. Tan, E. Khor, T.K. Tan, S.M. Wong, Talanta 45 (1998) 713–719.
16] A. Baxter, M. Dillon, K.D.A. Taylor, G.A.F. Robert, Int. J.  Biol. Macromol. 14 (1992)
166–169.
17] M.  Fenech, A.A. Morley, Mutat. Res. 147 (1985) 29–36.
18] D.A. Eastmond, J.D. Tucker, Environ. Mol. Mutagen. 13 (1989) 34–43.
19] R.R. Tice, P.W. Andrews, O. Hirai, N.P. Singh, in: C.R. Witmer, R.R. Snyder, D.J.
Jollow, J.J. Kocsis, I.G. Sipes (Eds.), Biological Reactive Intermediates IV, Molec-
ular and Cellular Effects and their Impact on Human Health, Plenum Press, New
York, 1991, pp. 157–164.
20] L. Casciola-Rosen, A. Rosen, M. Petri, M.  Schlissel, Proc. Natl. Acad. Sci. U. S. A.
93  (1996) 1624–1629.
21] M.  van Engeland, F.C. Ramaekers, B. Schutte, C.P. Reutelingsperger, Cytometry
24  (1996) 131–139.





   
23] A. Dhawan, M.  Bajpayee, D. Parmar, Cell Biol. Toxicol. 25 (2009) 5–32.
24] F. Chellat, M.  Tabrizian, S. Dumitriu, E. Chornet, P. Magny, C.H. Rivard, L. Yahia,
J.  Biomed. Mater. Res. A 51 (2000) 107–116.
25] L.C. Keong, A.S. Halim, Int. J. Mol. Sci. 10 (2009) 1300–1313.
26] F.-L. Mi, Y.-C. Tan, H.-F. Liang, H.-W. Sung, Biomaterials 23 (2002) 181–
191.
27] R.A. el-Zein, M.B. Schabath, C.J. Etzel, M.S. Lopez, J.D. Franklin, M.R. Spitz, Cancer
Res. 66 (2006) 6449–6456.
28] G. Krishna, M.L. Kropko, J.C. Theiss, Mutat. Res. Genet. Toxicol. 222 (1989)
63–69.
29] M.  Fenech, Nat. Protoc. 2  (2007) 1084–1104.
30] W. Liao, M.A. McNutt, W.-G. Zhu, Methods 48 (2009) 46–53.
31] M.  Tafazoli, A. Baeten, P. Geerlings, M. Kirsch-Volders, Mutagenesis 13 (1998)
115–126.
32] W.-P. Yuan, B. Liu, C.-H. Liu, X.-J. Wang, M.-S. Zhang, X.-M. Meng, X.-K. Xia,
World J. Gastroenterol. 15 (2009) 1339–1345.
33] H.J. Yoon, H.S. Park, H.S. Bom, Y.B. Roh, J.S. Kim, Y.H. Kim, Arch. Pharm. Res. 28
(2005) 1079–1085.
34] M.  Hasegawa, K. Yagi, S. Iwakawa, M. Hirai, Jpn. J. Cancer Res. 92 (2001)
459–466.
35] R. Kim, K. Tanabe, Y. Uchida, M. Emi, H. Inoue, T. Toge, Cancer Chemother.
Pharmacol. 50 (2002) 343–352.
36] H. Takimoto, M.  Hasegawa, K. Yagi, T. Nakamura, T. Sakaeda, M. Hirai, Drug
Metab. Pharmacokinet. 19 (2004) 76–82.
37] L. Qi, Z. Xu, Bioorg. Med. Chem. Lett. 16 (2006) 4243–4245.
38] C. Baudouin, L. Riancho, J.-M. Warnet, F. Brignole, Invest. Ophthalmol. Vis. Sci.
48  (2007) 4123–4128.
39] J.-Y. Je, Y.-S. Cho, S.-K. Ki, Bioorg. Med. Chem. Lett. 16 (2006) 2122–2126.
40] J.C. Fernandes, P. Eaton, H. Nascimento, L. Belo, S. Rocha, R. Vitorino, F. Amado, J.
Gomes, A. Santos-Silva, M.E. Pintado, F.X. Malcata, Biomacromolecular 9 (2008)
3346–3352.
41] J.C. Fernandes, P. Eaton, H. Nascimento, M.S. Gião, O.S. Ramos, L. Belo,
A.  Santos-Silva, M.E. Pintado, F.X. Malcata, Carbohydr. Polym. 79 (2010)
1101–1106.
42] H. Yang, C. Liu, D. Yang, H. Zhang, Z. Xi, J. Appl. Toxicol. 29 (2009) 69–78.
43] N. Arakaki, T. Kajihara, R. Arakaki, T. Ohnishi, J.A. Kazi, H. Nakashima, Y.
Daikuhara, J.  Biol. Chem. 274 (1999) 13541–13546.
44] A.K. Patlolla, C. Barnes, D. Hackett, P.B. Tchounwou, Int. J. Environ. Res. Public
Health 6  (2009) 643–653.
45] S.V. Lennon, S.J. Martin, T.G. Cotter, Cell Prolif. 24 (1991) 203–214.
